BioCentury | Apr 20, 2018
Clinical News

Symic reports Phase I/II data for SB-030 in peripheral vascular disease

...failure in patients with advanced peripheral vascular disease. SB-030 is a mimic of the proteoglycan decorin...
...Emeryville, Calif. Product: SB-030 (SBVC) Business: Cardiovascular Molecular target: Collagen Description: Mimic of the proteoglycan decorin...
BioCentury | Feb 21, 2018
Distillery Techniques

Chemistry

TECHNOLOGY: Tool compounds A peptidomimetic compound that inhibits the DCUND1-UBE2M interaction and neddylation of cullin 3 (CUL3) could be used to probe the role of the CUL3/DCN1 cullin-RING ligase complex in squamous cell lung carcinoma....
BioCentury | May 23, 2017
Financial News

Symic Bio raises $30M in series B

...SB-030 to prevent peripheral vein graft failure. The candidate is a mimic of the proteoglycan decorin...
BioCentury | Aug 15, 2016
Finance

Serving returns

...macromolecules found in the extracellular matrix. Symic's clinical-stage assets are SB-030 , a mimic of Decorin...
...antagonist to treat anemia Ph I Symic Biomedical Inc. First-in-class artificial proteoglycan mimetics: SB-030 mimics decorin...
BioCentury | Apr 7, 2016
Product R&D

Branching out

...of its two most advanced compounds. The company's lead compound, SB-030 , mimics the proteoglycan DCN...
...restrict tumor growth directly. "Heparan and decorin have been shown to have antitumor properties, and decorin...
...Biomedical Inc., Emeryville, Calif. Targets and Compounds Aggrecan ( ACAN ; CSPG1 ) DCN - Decorin...
BioCentury | Dec 2, 2015
Financial News

Symic raises $25M in series A-2 round

...in 2Q16. SB-061 is a mimic of the proteoglycan aggrecan. SB-030 is a mimic of decorin...
BioCentury | Nov 9, 2015
Clinical News

SB-030: Phase I/II started

...Product: SB-030 (formerly SBCV-030 ) Business: Cardiovascular Molecular target: Collagen Description: Mimic of the proteoglycan decorin...
BioCentury | Jan 5, 2015
Emerging Company Profile

Mimicking proteoglycans

...natural proteoglycans susceptible to degradation. One of Symic's two leads is a synthetic mimic of decorin...
...proliferation of smooth muscle cells and causing hyperplasia, or thickening of blood vessel walls. The decorin...
...half fail within a year. Unpublished data in pigs showed an AVF treated with a decorin...
BioCentury | Feb 22, 2000
Clinical News

ImuLyme: Discontinued Development

...will focus on development of a second-generation multiple antigen vaccine that will contain B. burgdorferi decorin...
BioCentury | Jul 12, 1999
Clinical News

MedImmune Inc. preclinical data

...from Texas A&M University. MedImmune Inc. (MEDI), Gaithersburg, Md. Product: Lyme disease vaccine combination of decorin...
Items per page:
1 - 10 of 16